| 1 |
Boyd A, Miailhes P, Chas J, Valantin MA, Yazdanpanah Y, Rosenthal E, Chevaliez S, Piroth L, Rougier H, Peytavin G, Pialoux G, Girard PM, Lacombe K. Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM. J Antimicrob Chemother 2020;75:1961-8. [PMID: 32306039 DOI: 10.1093/jac/dkaa091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 2 |
Liu J, Zhang Y, Wu B, Wang S, Bin-Chia Wu D, You R. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China. Front Pharmacol 2021;12:717504. [PMID: 34721016 DOI: 10.3389/fphar.2021.717504] [Reference Citation Analysis]
|
| 3 |
Calvaruso V, Petta S, Ferraro D, La Mantia C, Gibilaro G, Reina G, Di Maio VC, Licata A, Ceccherini-Silberstein F, Di Marco V, Craxì A. Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. Dig Liver Dis 2021:S1590-8658(21)00776-3. [PMID: 34593348 DOI: 10.1016/j.dld.2021.09.007] [Reference Citation Analysis]
|
| 4 |
Abergel A, Asselah T, Mallat A, Chanteranne B, Faure F, Larrey D, Gournay J, Loustaud-Ratti V, Di Martino V, Fouchard-Hubert I, Pol S, Bailly F, Samuel D, Tran A, Dodel M, Andant N, Lamblin G, Muti L, Reymond M, Teilhet C, Pereira B, Buchard B. Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. Liver Int 2020;40:1853-9. [PMID: 32383275 DOI: 10.1111/liv.14502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 5 |
Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-81. [PMID: 33428488 DOI: 10.1080/14787210.2021.1874351] [Reference Citation Analysis]
|
| 6 |
Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
|
| 7 |
Parczewski M, Janczewska E, Pisula A, Dybowska D, Łojewski W, Witor A, Wawrzynowicz-Syczewska M, Socha Ł, Krygier R, Knysz B, Musialik J, Urbańska A, Scheibe K, Jaroszewicz J. HCV resistance-associated substitutions following direct-acting antiviral therapy failure - Real-life data from Poland. Infect Genet Evol 2021;93:104949. [PMID: 34087494 DOI: 10.1016/j.meegid.2021.104949] [Reference Citation Analysis]
|
| 8 |
Lee JJ, Wei YJ, Lin MY, Niu SW, Hsu PY, Huang JC, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Huang CF, Chiu YW, Chuang WL, Yu ML. The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. PLoS One 2020;15:e0242601. [PMID: 33216807 DOI: 10.1371/journal.pone.0242601] [Reference Citation Analysis]
|
| 9 |
Hsu SJ, Enkhzaya S, Lin YY, Tseng TC, Khosbayar T, Tsai CH, Wang TS, Enkhtuya D, Ivshinkhorol D, Naranzul N, Jargalsaikhan B, Amarsanaa J, Baatarkhuu O, Kao JH. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. J Formos Med Assoc 2020;119:712-9. [PMID: 31672433 DOI: 10.1016/j.jfma.2019.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 10 |
Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association 2020;119:1019-40. [DOI: 10.1016/j.jfma.2020.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
|
